title: First-pass metabolism of peptide drugs in rat perfused liver.
abstract: To elucidate the extent and mechanisms of the first-pass metabolism of peptide drugs in the liver after oral administration, a liver perfusion study was performed in rats using metkephamid, a stable analogue of methionine enkephalin, and thyrotropin-releasing hormone (TRH), as model peptides. The fraction of intact metkephamid recovered after single-pass constant perfusion through rat liver reached steady-state very quickly, and it was concluded that metkephamid was hydrolysed enzymatically at the surface of hepatocytes or endothelial cells of microvessels, or both, rather than being taken up by hepatocytes. The fraction of metkephamid recovered intact was approximately 40% under protein-free conditions but increased to 70-75% on addition of bovine serum albumin (BSA) to the perfusate. The fraction of metkephamid bound to BSA was approximately 50% under these conditions, implying that only the free fraction of metkephamid in the plasma was metabolized in the liver. Calculations based on the tube model showed that approximately 30-35% of metkephamid absorbed from the intestine undergoes first-pass metabolism before entering the systemic circulation in-vivo. In contrast, the fraction of TRH metabolized in the liver was less than 10%, indicating a remarkably low contribution of first-pass metabolism to the bioavailability of TRH. These results show that hepatic first-pass metabolism of metkephamid contributes to its low systemic bioavailability. After intestinal absorption free metkephamid is rapidly hydrolysed on the surface of hepatocytes or endothelial cells, rather than being taken up by hepatocytes. This information has important implications in the oral delivery of many kinds of peptide.
authors.affiliation: Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Taki
authors.forename: T
authors.initials: T
authors.lastname: Sakane
authors.forename: T
authors.initials: T
authors.lastname: Nadai
authors.forename: H
authors.initials: H
authors.lastname: Sezaki
authors.forename: G L
authors.initials: GL
authors.lastname: Amidon
authors.forename: P
authors.initials: P
authors.lastname: Langguth
authors.forename: S
authors.initials: S
authors.lastname: Yamashita
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics; D001682:Biological Availability; D002417:Cattle; D004744:Enkephalin, Methionine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics; D007408:Intestinal Absorption; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012710:Serum Albumin, Bovine / Q000378:metabolism / Q000494:pharmacology; D013973:Thyrotropin-Releasing Hormone / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D012710:Serum Albumin, Bovine; D004744:Enkephalin, Methionine; D013973:Thyrotropin-Releasing Hormone; C028208:metkephamid